FDA approves MyocondaR IND for MAP in Crohn's Disease
SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX: GIA) today
announced that the US Food and Drug Administration (FDA) has
approved the Company's Investigational New Drug application (IND)
for the clinical development of MyocondaR
to treat patients with
Crohn's Disease infected with Mycobacterium ...